The Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive disease that weakens muscles and impacts physical function. ALS affects nerve cells in the brain and spinal cord, causing loss of muscle control. Currently, there is no cure available for ALS and the available treatment options provide modest improvement in symptoms and help extend survival. Some of the major treatments for ALS include Rilutek, Radicava, Tiglutik, and generic riluzole. However, the market is witnessing significant drug development and pipeline products to address the unmet needs.
The Global Amyotrophic Lateral Sclerosis Treatment Market is estimated to be valued at US$ 692.77 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the Amyotrophic Lateral Sclerosis Treatment market are Orion Corporation, Bausch Health Companies Inc., CYTOKINETICS, INC., Aquestive Therapeutics, Inc., Sanofi ,Covis Pharma, Sun Pharmaceuticals Industries Ltd, Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Limited, ViroMed Co., Ltd, Ionis Pharmaceuticals, Genervon Biopharmaceuticals, LLC, Biogen, Orphazyme A/S, Apotex Inc, Neuralstem, Inc., Implicit Bioscience, F. Hoffmann-La Roche Ltd, AB Science, and ADVANZ PHARMA.
The rising awareness about ALS and available treatment options is driving the demand in the market. Various initiatives by governments and non-profit organizations are helping increase awareness.
Technological advancements are allowing development of various treatment modalities for ALS. Companies are exploring gene therapy, stem cell therapy and other novel therapeutic approaches to manage and slow disease progression.
Market Trends
Growing pipeline of drugs - Several pharmaceutical companies have active drug pipeline to develop new treatment options for ALS. Drugs in phase 3 trials include Tofersen by Biogen, Bomedemstat by Orphazyme A/S and Masitinib by AB Science.
Focus on identifying biomarkers - Researchers are investing efforts to identify reliable biomarkers to help diagnose ALS earlier and also help assess effectiveness of new treatments in clinical trials. Identification of biomarkers can accelerate drug development process.
Market Opportunities
Stem cell therapy - Mesenchymal stem cells, neural stem cells and induced pluripotent stem cells are under research for ALS. Favorable results in clinical trials can boost the stem cell therapy segment.
Combination therapy approach - Combining available drugs with pipeline candidates or non-drug treatments holds potential to provide improved outcomes. Developing optimized combination regimens remains an active area of research.
Impact of COVID-19 on Amyotrophic Lateral Sclerosis Treatment Market
The COVID-19 pandemic has significantly impacted the growth of the Amyotrophic Lateral Sclerosis treatment market. The implementation of lockdowns and social distancing measures disrupted supply chains and delayed ongoing clinical trials. Healthcare resources were shifted to focus on COVID-19 patients, which reduced accessibility to routine treatments and diagnosis of ALS. This led to underdiagnosis and delayed treatment initiation during the pandemic. Telemedicine saw increased adoption to provide continued care to ALS patients, however, the ability to conduct in-person neurological examinations and tests was limited.
With lockdowns now being lifted, the market is seeing a recovery. However, the delays caused in 2020 and 2021 are expected to impact short-term growth forecasts. Companies are developing initiatives like direct-to-patient drug delivery and home health services to ensure uninterrupted care. Telehealth is also being expanded to supplement in-clinic consultations long-term. Governments and private bodies have increased funding for ALS research to make up for lost time during the pandemic. New screening programs are targeting underdiagnosed regions to evaluate post-COVID prevalence. If supply chains stabilize and clinical trials resume at full pace, pre-COVID market projections can be achieved by 2024.
In terms of geographical segmentation, North America accounts for the largest share of the Amyotrophic Lateral Sclerosis treatment market in terms of value. This is attributed to rising disease prevalence, availability of advanced treatments, and high healthcare spending in the region. However, Asia Pacific is expected to witness the fastest growth during the forecast period due to growing medical infrastructure, large patient pools, and increasing focus on rare disease diagnosis and management in developing countries.
Asia Pacific expected to witness fastest growth for Amyotrophic Lateral Sclerosis treatment market. The region has a huge patient population with increasing diagnosis rates of rare conditions like ALS. Countries like China and India are investing heavily in healthcare advancements. Rising incomes are enhancing affordability of high-cost specialty treatments in the region. Greater regulatory approvals are expanding treatment options. Additionally, the region did not witness as severe pandemic disruptions as other regions. With economies recovering strongly, overall healthcare spending is projected to drive above-average market growth for ALS treatments in Asia Pacific.
sayabonde
21 Blog posts
